ZymoGenetics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seattle WA United States (1981)
Status: Acquired by Bristol-Myers Squibb (2010)

Organization Overview

First Clinical Trial
2004
NCT00095108
First Marketed Drug
2008
thrombin (human coagulation factor iia) (Recombinant) (Recothrom)
First NDA Approval
2008
thrombin (human coagulation factor iia) (Recombinant) (Recothrom)
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zymogenetics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Loss, Surgical (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Infections (Phase 2)

Kidney Neoplasms (Phase 1)

Lupus Nephritis (Phase 3)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 1)

Nephritis (Phase 3)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 11